Corrigendum to "Stress biomarkers as predictors of transition to psychosis in at-risk mental states: Roles for cortisol, prolactin and albumin" [J. Psychiatr. Res. 60 (2015) 163-169], doi: 10.1016/j.jpsychires.2014.10.011;Stress biomarkers as predictors of transition to psychosis in at-risk mental states: Roles for cortisol, prolactin and albumin

Journal of Psychiatric Research

Volumn 60, Issue , 2015, Pages 163-169

  Labad, Javier ^a   Stojanovic Pérez, Alexander ^a   Montalvo, Itziar ^b   Solé, Montse ^a   Cabezas, Ángel ^a   Ortega, Laura ^a   Moreno, Irene ^a   Vilella, Elisabet ^a   Martorell, Lourdes ^a   Reynolds, Rebecca M ^c   Gutiérrez Zotes, Alfonso ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b Critical Care Centre   (Spain)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Albumin; At risk mental states; Cortisol; Hypothalamic pituitary adrenal axis; Prolactin; Psychosis; Stress

Indexed keywords

ALBUMIN; ARIPIPRAZOLE; C REACTIVE PROTEIN; DULOXETINE; FIBRINOGEN; HYDROCORTISONE; MIRTAZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; BIOLOGICAL MARKER; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; AROUSAL; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE RELEASE; LIFE STRESS; MALE; MENTAL HEALTH; PATHOGENESIS; PERCEIVED STRESS SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTOR VARIABLE; PROLACTIN BLOOD LEVEL; PSYCHOSIS; BLOOD; CASE CONTROL STUDY; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; PSYCHOLOGY; RISK FACTOR; SALIVA; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PITUITARY-ADRENAL SYSTEM; PROLACTIN; PSYCHOTIC DISORDERS; RISK FACTORS; SALIVA; SERUM ALBUMIN; YOUNG ADULT;

EID: 84918820057     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.01.012     Document Type: Erratum

References (50)

1. Aston J., Rechsteiner E., Bull N., Borgwardt S., Gschwandtner U., Riecher-Rössler A. Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry 2010, 34:1342-1344.
2. Beards S., Gayer-Anderson C., Borges S., Dewey M.E., Fisher H.L., Morgan C. Life events and psychosis: a review and meta-analysis. Schizophr Bull 2013, 39:740-747.
3. Borges S., Gayer-Anderson C., Mondelli V. Asystematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology 2013, 38:603-611.
4. Büschlen J., Berger G.E., Borgwardt S.J., Aston J., Gschwandtner U., Pflueger M.O., et al. Pituitary volume increase during emerging psychosis. Schizophr Res 2011, 125:41-48.
5. Champaneri S., Xu X., Carnethon M.R., Bertoni A.G., Seeman T., DeSantis A.S., et al. Diurnal salivary cortisol is associated with body mass index and waist circumference: the multiethnic study of atherosclerosis. Obesity (Silver Spring) 2013, 21:E56-63.
6. Chau S.Y., Mok C.C. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology 2003, 61:104-107.
7. Cohen S., Kamarck T., Mermelstein R. Aglobal measure of perceived stress. JHealth Soc Behav 1983, 24:385-396.
8. Collip D., Nicolson N.A., Lardinois M., Lataster T., van Os J., Myin-Germeys I. Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. Psychol Med 2011, 41:2305-2315.
9. Corcoran C.M., Smith C., McLaughlin D., Auther A., Malaspina D., Cornblatt B. HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr Res 2012, 135:170-174.
10. Cornblatt B.A., Lencz T., Smith C.W., Olsen R., Auther A.M., Nakayama E., et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. JClin Psychiatry 2007, 68:546-557.
11. Day F.L., Valmaggia L.R., Mondelli V., Papadopoulos A., Papadopoulos I., Pariante C.M., et al. Blunted cortisol awakening response in people at ultra high risk of developing psychosis. Schizophr Res 2014, 158:25-31.
12. Flatow J., Buckley P., Miller B.J. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013, 74:400-409.
13. Fournier M., Ferrari C., Baumann P.S., Polari A., Monin A., Bellier-Teichmann T., et al. Impaired metabolic reactivity to oxidative stress in early psychosis patients. Schizophr Bull 2014 Mar 31, [Epub ahead of print].
14. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rössler A., Schultze-Lutter F., et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
15. Garcia-Rizo C., Fernandez-Egea E., Oliveira C., Justicia A., Parellada E., Bernardo M., et al. Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res 2012, 134:16-19.
16. Garner B., Pariante C.M., Wood S.J., Velakoulis D., Phillips L., Soulsby B., et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol Psychiatry 2005, 58:417-423.
17. Grabemann M., Mette C., Zimmermann M., Wiltfang J., Kis B. Serum albumin correlates with affective prosody in adult males with attention-deficit hyperactivity disorder. Psychiatry Res 2014, 217:198-201.
18. Holmes T., Rahe R. The social readjustment scale. JPsychosom Res 1967, 11:213-218.
19. Huang S.Y., Chiu C.C., Shen W.W., Chang H.C., Wu P.L., Su K.P. Hypoalbuminemia in drug-free patients with major depressive disorder compared with a dietary matched control group: a clinical meaning beyond malnutrition. Eur Neuropsychopharmacol 2005, 15:227-230.
20. Huang T.-L. Decreased serum albumin levels in Taiwanese patients with schizophrenia. Psychiatry Clin Neurosci 2002, 56:627-630.
21. Inder W.J., Dimeski G., Russell A. Measurement of salivary cortisol in 2012 - laboratory techniques and clinical indications. Clin Endocrinol (Oxf) 2012, 77:645-651.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
23. Kirkpatrick B., Miller B.J. Inflammation and schizophrenia. Schizophr Bull 2013, 39:1174-1179.
24. Lennartsson A.K., Jonsdottir I.H. Prolactin in response to acute psychosocial stress in healthy men and women. Psychoneuroendocrinology 2011, 36:1530-1539.
25. López-Medrano F., Cervera R., Trejo O., Font J., Ingelmo M. Steroid induced psychosis in systemic lupus erythematosus: a possible role of serum albumin level. Ann Rheum Dis 2002, 61:562-563.
26. Manzanares N., Monseny R., Ortega L., Montalvo I., Franch J., Gutierrez-Zotes A., et al. Unhealthy lifestyle in early psychoses: the role of life stress and the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology 2014, 39:1-10.
27. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
28. Mizrahi R., Addington J., Rusjan P.M., Suridjan I., Ng A., Boileau I., et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 2012, 71:561-567.
29. Montalvo I., Gutiérrez-Zotes A., Creus M., Monseny R., Ortega L., Franch J., et al. Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. PLoS One 2014, 9:e89428.
30. Pae C.U., Paik I.H., Lee C., Lee S.J., Kim J.J., Lee C.U. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 2004, 50:54-56.
31. Pariante C.M., Dazzan P., Danese A., Morgan K.D., Brudaglio F., Morgan C., et al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005, 30:1923-1931.
32. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T.-J., Griffin J.L., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004, 9:684-697.
33. Pruessner J.C., Kirschbaum C., Meinlschmid G., Hellhammer D.H. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 2003, 28:916-931.
34. Pruessner M., Iyer S.N., Faridi K., Joober R., Malla A.K. Stress and protective factors in individuals at ultra-high risk for psychosis, first episode psychosis and healthy controls. Schizophr Res 2011, 129:29-35.
35. Reddy R., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003, 62:205-212.
36. Riecher-Rössler A., Rybakowski J.K., Pflueger M.O., Beyrau R., Kahn R.S., Malik P., et al. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol Med 2013, 43:2571-2582.
37. Roca M., Gili M., Garcia-Campayo J., Armengol S., Bauza N., Garcia-Toro M. Stressful life events severity in patients with first and recurrent depressive episodes. Soc Psychiatry Psychiatr Epidemiol 2013, 48:1963-1969.
38. Roche M., Rondeau P., Singh N.R., Tarnus E., Bourdon E. The antioxidant properties of serum albumin. FEBS Lett 2008, 582:1783-1787.
39. Rössler W., Riecher-Rössler A., Angst J., Murray R., Gamma A., Eich D., et al. Psychotic experiences in the general population: a twenty-year prospective community study. Schizophr Res 2007, 92:1-14.
40. Sobrinho L.G. Prolactin, psychological stress and environment in humans: adaptation and maladaptation. Pituitary 2003, 6:35-39.
41. Stojanovic A., Martorell L., Montalvo I., Ortega L., Monseny R., Vilella E., et al. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 2014, 41:23-32.
42. Sugranyes G., Thompson J.L., Corcoran C.M. HPA-axis function, symptoms, and medication exposure in youths at clinical high risk for psychosis. JPsychiatr Res 2012, 46:1389-1393.
43. Thalacker-Mercer A.E., Campbell W.W. Dietary protein intake affects albumin fractional synthesis rate in younger and older adults equally. Nutr Rev 2008, 66:91-95.
44. Valmaggia L.R., Day F.L., Jones C., Bissoli S., Pugh C., Hall D., et al. Cannabis use and transition to psychosis in people at ultra-high risk. Psychol Med 2014, 44:2503-2512.
45. Walker E.F., Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev 1997, 104:667-685.
46. Walker E.F., Trotman H.D., Pearce B.D., Addington J., Cadenhead K.S., Cornblatt B.A., et al. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol Psychiatry 2013, 74:410-417.
47. Walter A., Studerus E., Smieskova R., Tamagni C., Rapp C., Borgwardt S.J., et al. Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis. CNS Spectr 2014, i:1-8.
48. Yao J.K., Leonard S., Reddy R.D. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 2004, 30:923-934.
49. Yao J.K., Reddy R., Van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000, 97:137-151.
50. Yung A.R., McGorry P.D. Prediction of psychosis: setting the stage. Br J Psychiatry Suppl 2007, 51:s1-s8.